Home › Companies › DBVT

DBV Technologies

DBVT Rare disease Lead: NDA Submitted 3 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-15

Pipeline (3 active programs)

Viaskin Peanut

DBV712

Protein

Peanut Allergy NDA Submitted topical

Viaskin Milk

DBV135

Protein

Cow's Milk Allergy topical
Eosinophilic Esophagitis topical

Technology platforms

Viaskin

Epicutaneous immunotherapy (EPIT) platform delivering biologically active compounds via intact skin using an adhesive patch; primary focus on food allergy and other immunological/autoimmune inflammatory conditions

Biotech Distilled coverage (3)

2026-06-29 UPDATE: DBV Technologies (DBVT) - The BLA Slips a Quarter
2026-03-28 UPDATE: DBV Technologies (DBVT) - FDA Hits Fast Forward 🔒 Paid
2025-12-22 DBV Technologies (DBVT): Scientific Due Diligence 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.